Literature DB >> 29306153

A pathogenetic role for M1 macrophages in peritoneal dialysis-associated fibrosis.

Qing Li1, Min Zheng1, Yueheng Liu2, Wei Sun1, Jun Shi1, Jie Ni1, Qiong Wang3.   

Abstract

Peritoneal fibrosis (PF) is a frequent complication of peritoneal dialysis (PD) accompanied by the infiltration of inflammatory cells. Recently, the function of macrophages in an inflammatory microenvironment during PD remains unknown. This study aimed to elucidate the role of distinct macrophage phenotypes in the progression of PF through macrophage depletion in a peritoneal dialysis-induced mouse model. After injection of 200 μl liposomal clodronate (LC) at the start of instillation PD fluids (PDFs), mice were injected with 100 μL LC every 4 days after the first time injection for longer macrophage depletion, while control mice were co-treated with PBS liposomes. For macrophages transfusion,primary macrophages (M0) were stimulated into M1 and M2 macrophages and transfuritoneal fibrosis (PF) is a frequent complication of peritoneal dialysis (PD) accompanied by the infiltration of inflammatory cells. Recently, the function of macrophages in an inflammatory microenvironment during PD remains unknown. This study aimed to elucidate the role of distinct macrophage phenotypes in the progression of PF through macrophage depletion in a peritoneal dialysis-induced mouse model. After injection of 200 μl liposomal clodronate (LC) at the start of instillation PD fluids (PDFs), mice were injected with 100 μL LC every 4 days after the first time injection for longer macrophage depletion, while control mice were co-treated with PBS liposomes. For macrophages transfusion,primary macrophages (M0) were stimulated into M1 and M2 macrophages and transfused into the mice the next day after each LC injection. Mice were sacrificed after 6 weeks of PDFs treatment for the assessment of histological changes, ECM deposition and peritoneal ultrafiltration function. Systemic monocyte/macrophage depletion resulted in less severe structural alterations, including thickening and cubic transformation of mesothelial cells, fibrin deposition, fibrous capsule formation, and interstitial fibrosis. A strong reduction of alpha-smooth muscle actin (α-SMA) and fibronectin expression, as well as an increased E-cadherin expression was also observed, indicating an overall inhibition of peritoneal fibrosis in macrophages depletion mice.M1 macrophage reperfusion showed a significant increase in histological damages, ECM deposition and peritoneal ultrafiltration functional decline compared with those of the M2 and control groups. TLR4 expression was enhanced in M1 macrophage-treated group. These results suggest that M1 macrophages are an important mediator of peritoneal fibrosis.
Copyright © 2017 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  M1 macrophages; Macrophage depletion; Peritoneal dialysis-associated fibrosis

Mesh:

Substances:

Year:  2018        PMID: 29306153     DOI: 10.1016/j.molimm.2017.12.023

Source DB:  PubMed          Journal:  Mol Immunol        ISSN: 0161-5890            Impact factor:   4.407


  10 in total

1.  Matrix Metallopeptidase 14: A Candidate Prognostic Biomarker for Diffuse Large B-Cell Lymphoma.

Authors:  Chengliang Yin; Junyan Zhang; Ming Shen; Zhenyang Gu; Yan Li; Wanguo Xue; Jinlong Shi; Wenrong Huang
Journal:  Front Oncol       Date:  2020-08-20       Impact factor: 6.244

2.  Macrophage depletion by clodronate attenuates bone morphogenetic protein-7 induced M2 macrophage differentiation and improved systolic blood velocity in atherosclerosis.

Authors:  Heidi Shoulders; Kaley H Garner; Dinender K Singla
Journal:  Transl Res       Date:  2018-07-25       Impact factor: 7.012

3.  Hepatocyte growth factor ameliorates methylglyoxal-induced peritoneal inflammation and fibrosis in mouse model.

Authors:  Haruhito Yoshimine; Shiroh Tanoue; Yutaro Ibi; Masato Minami; Mai Nakahara; Koki Tokunaga; Shuji Kanmura; Akio Ido
Journal:  Clin Exp Nephrol       Date:  2021-04-28       Impact factor: 2.801

4.  Mechanisms of Peritoneal Fibrosis: Focus on Immune Cells-Peritoneal Stroma Interactions.

Authors:  Michela Terri; Flavia Trionfetti; Claudia Montaldo; Marco Cordani; Marco Tripodi; Manuel Lopez-Cabrera; Raffaele Strippoli
Journal:  Front Immunol       Date:  2021-03-29       Impact factor: 7.561

5.  Exosomes derived from inflammatory myoblasts promote M1 polarization and break the balance of myoblast proliferation/differentiation.

Authors:  Zhi-Wen Luo; Ya-Ying Sun; Jin-Rong Lin; Bei-Jie Qi; Ji-Wu Chen
Journal:  World J Stem Cells       Date:  2021-11-26       Impact factor: 5.326

6.  Macrophage-derived apoptotic vesicles regulate fate commitment of mesenchymal stem cells via miR155.

Authors:  Yuan Zhu; Xiao Zhang; Kunkun Yang; Yuzi Shao; Ranli Gu; Xuenan Liu; Hao Liu; Yunsong Liu; Yongsheng Zhou
Journal:  Stem Cell Res Ther       Date:  2022-07-16       Impact factor: 8.079

7.  Delayed Administration of Nintedanib Ameliorates Fibrosis Progression in CG-Induced Peritoneal Fibrosis Mouse Model.

Authors:  Binbin Cui; Chao Yu; Shenglei Zhang; Xiying Hou; Yi Wang; Jun Wang; Shougang Zhuang; Feng Liu
Journal:  Kidney Dis (Basel)       Date:  2022-04-11

Review 8.  Fibronectin in Cancer: Friend or Foe.

Authors:  Tsung-Cheng Lin; Cheng-Han Yang; Li-Hsin Cheng; Wen-Tsan Chang; Yuh-Rong Lin; Hung-Chi Cheng
Journal:  Cells       Date:  2019-12-20       Impact factor: 6.600

Review 9.  IL-17A as a Potential Therapeutic Target for Patients on Peritoneal Dialysis.

Authors:  Vanessa Marchant; Antonio Tejera-Muñoz; Laura Marquez-Expósito; Sandra Rayego-Mateos; Raul R Rodrigues-Diez; Lucia Tejedor; Laura Santos-Sanchez; Jesús Egido; Alberto Ortiz; Jose M Valdivielso; Donald J Fraser; Manuel López-Cabrera; Rafael Selgas; Marta Ruiz-Ortega
Journal:  Biomolecules       Date:  2020-09-24

10.  Ongoing Exposure to Peritoneal Dialysis Fluid Alters Resident Peritoneal Macrophage Phenotype and Activation Propensity.

Authors:  Tara E Sutherland; Tovah N Shaw; Rachel Lennon; Sarah E Herrick; Dominik Rückerl
Journal:  Front Immunol       Date:  2021-07-27       Impact factor: 7.561

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.